ZIOPHARM Oncology Inc (NASDAQ:ZIOP) Given Consensus Rating of “Hold” by Brokerages
ZIOPHARM Oncology Inc (NASDAQ:ZIOP) has been given an average rating of “Hold” by the six analysts that are covering the stock, MarketBeat reports. Four investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $16.50.
Several research analysts have recently issued reports on the stock. ValuEngine raised shares of ZIOPHARM Oncology from a “sell” rating to a “hold” rating in a research note on Monday, July 17th. HC Wainwright set a $10.00 price objective on shares of ZIOPHARM Oncology and gave the stock a “buy” rating in a research note on Tuesday, August 1st. Zacks Investment Research raised shares of ZIOPHARM Oncology from a “sell” rating to a “hold” rating in a research note on Wednesday, April 26th. Finally, BidaskClub raised shares of ZIOPHARM Oncology from a “sell” rating to a “hold” rating in a research note on Tuesday.
TRADEMARK VIOLATION NOTICE: This piece was first posted by Watch List News and is owned by of Watch List News. If you are accessing this piece on another domain, it was copied illegally and reposted in violation of US & international copyright laws. The correct version of this piece can be read at https://www.watchlistnews.com/ziopharm-oncology-inc-nasdaqziop-given-consensus-rating-of-hold-by-brokerages/1472488.html.
ZIOPHARM Oncology (NASDAQ ZIOP) opened at 5.45 on Friday. The firm has a 50-day moving average of $5.95 and a 200 day moving average of $6.33. The company’s market cap is $766.44 million. ZIOPHARM Oncology has a 52-week low of $4.84 and a 52-week high of $7.88.
ZIOPHARM Oncology (NASDAQ:ZIOP) last issued its earnings results on Monday, July 31st. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.13). The business had revenue of $1.60 million during the quarter, compared to the consensus estimate of $1.66 million. The firm’s revenue for the quarter was down 5.9% compared to the same quarter last year. During the same period last year, the business posted ($1.01) EPS. Equities research analysts expect that ZIOPHARM Oncology will post ($0.54) earnings per share for the current fiscal year.
Several hedge funds have recently bought and sold shares of the stock. Mission Wealth Management LLC acquired a new stake in ZIOPHARM Oncology during the first quarter worth about $108,000. Oppenheimer & Co. Inc. increased its position in shares of ZIOPHARM Oncology by 50.0% in the second quarter. Oppenheimer & Co. Inc. now owns 18,000 shares of the biotechnology company’s stock worth $112,000 after buying an additional 6,000 shares during the last quarter. BB&T Securities LLC purchased a new position in shares of ZIOPHARM Oncology during the second quarter worth $112,000. Principal Financial Group Inc. increased its position in shares of ZIOPHARM Oncology by 7.5% in the second quarter. Principal Financial Group Inc. now owns 24,046 shares of the biotechnology company’s stock worth $150,000 after buying an additional 1,673 shares during the last quarter. Finally, Ballentine Partners LLC purchased a new position in shares of ZIOPHARM Oncology during the second quarter worth $162,000. Institutional investors own 38.20% of the company’s stock.
ZIOPHARM Oncology Company Profile
ZIOPHARM Oncology, Inc is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease.
Receive News & Ratings for ZIOPHARM Oncology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.